Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial


Early enteral vitamin is essential for stopping malnutrition and bettering outcomes
in sufferers with extreme stroke, however earlier trials have supplied conflicting outcomes
concerning the optimum dietary technique. We aimed to match the efficacy and security
of three enteral feeding methods in sufferers with extreme stroke.


The Optimizing Early Enteral Nutrition in Severe Stroke (OPENS) research was a multicentre,
investigator-initiated, potential, open-label, randomised managed trial, with
blinded end result evaluation, in 16 tertiary and district normal hospitals within the west
of China. Adult sufferers with acute extreme ischaemic or haemorrhagic stroke (Glasgow
Coma Scale rating ≤12 or National Institutes of Health Stroke Scale rating ≥11 on admission)
who have been anticipated to obtain enteral vitamin for greater than 7 days have been randomly
assigned (1:1:1) to full enteral vitamin (70–100% of estimated caloric necessities),
modified full enteral vitamin (full enteral vitamin plus prokinetic brokers), or
hypocaloric enteral vitamin (40–60% of estimated caloric necessities) by way of a centralised
web-based randomisation system. The assigned vitamin was initiated inside 24 h after
enrolment and continued for 7 days. The computer-generated randomisation sequence
was ready by a statistician not concerned with the remainder of the research. Randomisation
was performed with an automatic permuted block measurement of six. The allocation was unblinded
to individuals and investigators. The main efficacy end result was the proportion
of individuals with poor end result (modified Rankin Scale rating ≥3) at day 90 and the
prespecified main security end result was mortality at day 90, assessed within the intention-to-treat
inhabitants. The trial is registered with, NCT02982668.


Between Jan 15, 2017, and Sept 23, 2020, 321 sufferers have been randomly assigned (107
in every group) and 315 sufferers (175 [56%] males, median age 71 years, IQR 60–78) have been
included within the remaining evaluation. The research was terminated forward of schedule on Sept
23, 2020, as a result of a big distinction between teams was detected in mortality.
The proportion of individuals with poor outcomes at 90 days didn’t differ (modified
full enteral vitamin 86 [82%] of 105 sufferers vs full enteral vitamin 85 [80%] of 106 sufferers, adjusted odds ratio [OR] 0·87, 95%
CI 0·41–1·86, p=0·721; hypocaloric enteral vitamin 76 [73%] of 104 sufferers vs full enteral vitamin 0·61, 0·30–1·27, p=0·186; hypocaloric enteral vitamin vs modified full enteral vitamin 0·70, 0·34–1·46, p=0·340). Hypocaloric enteral vitamin
confirmed considerably greater 90-day mortality than did modified full enteral vitamin
(35 [34%] of 104 sufferers vs 18 [17%] of 105 sufferers, adjusted OR 2·89, 95% CI 1·46–5·72; p=0·0023), whereas
the distinction was not vital between hypocaloric enteral vitamin and full
enteral vitamin (24 [23%] of 106 sufferers; adjusted OR 1·92, 95% CI 1·00–3·69; p=0·049),
and between modified full enteral vitamin and full enteral vitamin (adjusted OR
0·61, 0·29–1·28; p=0·187). The most typical hostile occasion was pneumonia, the incidence
of which confirmed no vital distinction amongst teams (full enteral vitamin 82
[78%] of 105 sufferers, modified full enteral vitamin 83 [81%] of 103 sufferers, hypocaloric
enteral vitamin 78 [75%] of 104 sufferers; p=0·625).


In the early part of extreme stroke, modified full enteral vitamin or hypocaloric
enteral vitamin didn’t considerably scale back the chance of a poor outcomes in contrast
with full enteral vitamin over a 90-day interval. Hypocaloric enteral vitamin would possibly
be related to elevated mortality in contrast with modified full enteral vitamin.
Further research are wanted to analyze whether or not modified full enteral vitamin
could be the optimum technique.


Shaanxi province Key Research and Development Project.

Recommended For You

About the Author: Adrian

Leave a Reply